paying for breakthrough eye therapies (biologics, biosimilars & gene therapies)
TRANSCRIPT
Participants:
Trex Topping, MDOphtahlmic Consultants of Boston
John Thompson, MDRetina Specialists
Jay Duker, MDHemera Biosciences
Joshua Schimmer, MD Senior Research Analyst
Piper Jaffray
Co-Moderated By:
Tarek Hassan, MDAssociated Retinal Consultants
Gilbert H. Kliman, MD Managing Director InterWest Partners
Paying for Breakthrough Eye Therapies (Biologics, Biosimilars & Gene Therapies)
Panel Discussion
1. Which drug therapy would you use on your own eye for
wet AMD if all the drugs costs the same?
PIPER JAFFRAY | 5
Trends in Drug Pricing: Pressure Across the Board
• Factors driving pricing pressure:
Industry growth ($450B/yr+)
Increasing competition
Consolidation of payors
Aging population straining budgets
• Source:
The industry is steadily shifting to ‘value-based’ pricing and most new drugs will have to fit into this paradigm
• Ophthalmology focus:
Only 2-3% of drug spend
Wet AMD biggest driver by far
Innovation in front/back of eye
Increasing # Orphan eye drugs
PIPER JAFFRAY | 6
Pricing Trends: Power Shifting To Payors
Price increases are being mostly offset by discounts/rebates. Payors have greater control over drug utilization than ever before
Source: IMS Health report
2. Payor dynamics seem to be driving patient care. Are AMD drug prices too high, or is the willingness to pay too
low?
PIPER JAFFRAY | 8
Biosimilar Pipelines Getting Full
• Source: biopharma.com
Long-list of biopharma players ranging from large biopharma companies down to small/mid global biosimilar companies in U.S., South Korea, India and beyond
Most advanced biosimilar Lucentis
program (Pfenex/PFE) is starting pivotal trials this
year
3. Assuming biosimilar anti-VEGFs are approved, where
will pricing come out and what will be the impact on
clinical practice?
PIPER JAFFRAY | 10
Innovation in Ophtho: Gene Therapy and BeyondCONTENT
• Source: Company reports
PUBLICLY TRADED COMPANIES PRIVATE COMPANIES
Company Clinical Preclinal Company Clinical Preclinical
Spark LCAChoroideremia RP, LHON NightstaRx Choroideremia TBD
Oxford Biomed AMD, Stargardt, Usher
Corneal graft Retro-Sense Optogenics/ RP, AMD Optogenics
AGTC XLRS, achromatopsia XLRP, AMD Gensight LHON RP, dry AMD
Adverum AMD XLRS, color vision MeiraGTx N/A LCA, XLRP, AMD,
achromatopsia
REGENX-BIO AMD 4D Molecular Choroideremia
Editas LCA10
4. If one-time gene therapy proves to be a successful therapy for orphan retina diseases, how should it be
priced?
Can this pricing model work for common conditions such
as AMD?